D. Hay

发表

Pharmacology of the human CGRP1 receptor in Cos 7 cells

R. J. Bailey, D. Hay, 2006, Peptides.

Characterization of the structure of RAMP1 by mutagenesis and molecular modeling.

D. Hay, J. Simms, M. Wheatley, 2006, Biophysical Journal.

Cryo-EM structure of the active, Gs-protein complexed, human CGRP receptor

W. Baumeister, P. Sexton, A. Christopoulos, 2018, Nature.

GPCR modulation by RAMPs.

P. Sexton, D. Hay, D. Poyner, 2006, Pharmacology & therapeutics.

Receptor Activity-Modifying Proteins (RAMPs): New Insights and Roles.

A. Pioszak, D. Hay, 2016, Annual review of pharmacology and toxicology.

N-Glycosylation of Asparagine 130 in the Extracellular Domain of the Human Calcitonin Receptor Significantly Increases Peptide Hormone Affinity.

A. Pioszak, D. Hay, Virginie H. Sjoelund, 2017, Biochemistry.

Calcitonin and amylin receptor peptide interaction mechanisms. INSIGHTS INTO PEPTIDE-BINDING MODES AND ALLOSTERIC MODULATION OF THE CALCITONIN RECEPTOR BY RECEPTOR ACTIVITY-MODIFYING PROTEINS.

A. Pioszak, D. Hay, Sangmin Lee, 2016, The Journal of Biological Chemistry.

Synthesis of isotopically labelled αCGRP8-37 and its lipidated analogue.

M. Brimble, D. Hay, P. Harris, 2020, Journal of labelled compounds & radiopharmaceuticals.

Differential activation of G‐proteins by μ‐opioid receptor agonists

M. Glass, D. Hay, J. Northup, 2006, British journal of pharmacology.

Structure–activity relationships for α‐calcitonin gene‐related peptide

D. Hay, D. Poyner, D. Rathbone, 2013, British journal of pharmacology.

Effects of Melanocortin Receptor Ligands on Thyrotropin‐Releasing Hormone Release: Evidence for the Differential Roles of Melanocortin 3 and 4 Receptors

D. Smith, S. Bloom, M. Ghatei, 2002, Journal of neuroendocrinology.

CGRP and the Calcitonin Receptor are Co-Expressed in Mouse, Rat and Human Trigeminal Ganglia Neurons

D. Hay, S. O'Carroll, A. Russo, 2022, Frontiers in Physiology.

Pharmacological characterization and investigation of N-terminal loop amino acids of adrenomedullin 2 that are important for receptor activation.

M. Brimble, D. Hay, P. Harris, 2019, Biochemistry.

Amyloidogenicity, Cytotoxicity, and Receptor Activity of Bovine Amylin: Implications for Xenobiotic Transplantation and the Design of Nontoxic Amylin Variants.

D. Raleigh, A. Schmidt, Rebekah L. Bower, 2018, ACS chemical biology.

Update on the pharmacology of calcitonin/CGRP family of peptides: IUPHAR Review 25

D. Hay, D. Poyner, Michael L. Garelja, 2018, British journal of pharmacology.

CGRP Receptor Biology: Is There More Than One Receptor?

D. Hay, 2018, Handbook of experimental pharmacology.

CGRP and its receptors

D. Hay, C. Walker, 2017, Headache.

Amylin

D. Hay, 2017, Headache.

CGRP family of peptides : IUPHAR Review : ” X ” Running title : Pharmacology of the calcitonin / CGRP family

D. Hay, D. Poyner, Michael L. Garelja, 2017 .

Amylin structure–function relationships and receptor pharmacology: implications for amylin mimetic drug development

Rebekah L. Bower, D. Hay, 2016, British journal of pharmacology.

α-Calcitonin gene related peptide (α-CGRP) mediated lipid mobilization in 3T3-L1 adipocytes

G. Cooper, D. Hay, K. Loomes, 2014, Peptides.

Structure–activity relationships of the N-terminus of calcitonin gene-related peptide: key roles of alanine-5 and threonine-6 in receptor activation

M. Brimble, D. Hay, D. Poyner, 2013, British journal of pharmacology.

Secretin family (Class B) G protein‐coupled receptors – from molecular to clinical perspectives

D. Hay, D. Poyner, 2012, British journal of pharmacology.

The role of glutamic acid 73 in adrenomedullin interactions with rodent AM2 receptors

D. Hay, A. Halim, 2012, Peptides.

Adrenomedullin receptors: molecular identity and function

D. Hay, David M. Smith, 2001, Peptides.

CL/RAMP2 and CL/RAMP3 produce pharmacologically distinct adrenomedullin receptors: a comparison of effects of adrenomedullin22–52, CGRP8–37 and BIBN4096BS

D. Smith, D. Hay, D. Poyner, 2003, British journal of pharmacology.

Evidence that alpha-calcitonin gene-related peptide is a neurohormone that controls systemic lipid availability and utilization.

E. Kraegen, G. Cooper, D. Hay, 2008, Endocrinology.

Identification of N-Terminal Receptor Activity-Modifying Protein Residues Important for Calcitonin Gene-Related Peptide, Adrenomedullin, and Amylin Receptor Function

P. Sexton, A. Christopoulos, R. J. Bailey, 2008, Molecular Pharmacology.

International Union of Pharmacology. LXIX. Status of the Calcitonin Gene-Related Peptide Subtype 2 Receptor

R. Quirion, D. Hay, D. Poyner, 2008, Pharmacological Reviews.

A key role for tryptophan 84 in receptor activity-modifying protein 1 in the amylin 1 receptor

R. J. Bailey, D. Hay, J. Gingell, 2010, Peptides.

The pharmacology of Adrenomedullin 2/Intermedin

R. Quirion, D. Hay, D. Poyner, 2012, British journal of pharmacology.

Lipidated Calcitonin Gene-Related Peptide (CGRP) Peptide Antagonists Retain CGRP Receptor Activity and Attenuate CGRP Action In Vivo

Sung‐Hyun Yang, M. Brimble, Rebekah L. Bower, 2022, Frontiers in Pharmacology.

Mice lacking the neuropeptide alpha-calcitonin gene-related peptide are protected against diet-induced obesity.

E. Kraegen, G. Cooper, Xiaolin Li, 2010, Endocrinology.

Agonist bias and agonist‐dependent antagonism at corticotrophin releasing factor receptors

D. Hay, C. Walker, Zoe Tasma, 2020, Pharmacology research & perspectives.

Antagonism of CGRP Signaling by Rimegepant at Two Receptors

D. Hay, C. Walker, Andrew Siow, 2020, Frontiers in Pharmacology.

The pharmacology of adrenomedullin receptors and their relationship to CGRP receptors

D. Hay, D. Poyner, David M. Smith, 2004, Journal of Molecular Neuroscience.

A potent fluorescent calcitonin gene‐related peptide analogue enables visualization of receptor internalization

M. Brimble, D. Hay, D. Poyner, 2019, Peptide Science.

Receptor activity‐modifying protein‐dependent impairment of calcitonin receptor splice variant Δ(1–47)hCT(a) function

L. Miller, D. Hay, M. Dong, 2013, British journal of pharmacology.

Oxyntomodulin inhibits food intake in the rat.

D. Smith, S. Bloom, M. Ghatei, 2001, Endocrinology.

The preclinical pharmacology of BIBN4096BS, a CGRP antagonist.

D. Hay, D. Poyner, 2006, Cardiovascular drug reviews.

Structure–function analysis of amino acid 74 of human RAMP1 and RAMP3 and its role in peptide interactions with adrenomedullin and calcitonin gene-related peptide receptors

P. Sexton, D. Hay, D. Poyner, 2011, Peptides.

Adrenomedullin and calcitonin gene-related peptide receptors in endocrine-related cancers: opportunities and challenges.

D. Hay, D. Poyner, C. Walker, 2010, Endocrine-related cancer.

D. Hay, D. Poyner, C. Walker, 2010 .

CT, CGRP, Amylin, and Adrenomedullins

D. Hay, D. Poyner, 2009 .

A Single Pseudoproline and Microwave Solid Phase Peptide Synthesis Facilitates an Efficient Synthesis of Human Amylin 1–37

M. Brimble, D. Hay, P. Harris, 2012, International Journal of Peptide Research and Therapeutics.

Desensitisation of adrenomedullin and CGRP receptors

D. Hay, D. Poyner, David M. Smith, 2003, Regulatory Peptides.

A comparison of the actions of BIBN4096BS and CGRP8–37 on CGRP and adrenomedullin receptors expressed on SK‐N‐MC, L6, Col 29 and Rat 2 cells

D. Hay, D. Poyner, M. Schindler, 2002, British journal of pharmacology.

Comparison of the expression of calcitonin receptor‐like receptor (CRLR) and receptor activity modifying proteins (RAMPs) with CGRP and adrenomedullin binding in cell lines

D. Hay, D. Poyner, S. Legon, 2002, British journal of pharmacology.

Immunohistochemical detection of the calcitonin receptor-like receptor protein in the microvasculature of rat endothelium.

P. Facer, D. Hay, G. Mcgregor, 2003, European journal of pharmacology.

RAMPs and CGRP receptors.

D. Hay, J. Simms, D. Poyner, 2012, Advances in experimental medicine and biology.

Mapping the CGRP receptor ligand binding domain: tryptophan-84 of RAMP1 is critical for agonist and antagonist binding.

D. Hay, S. Kane, J. Gingell, 2010, Biochemical and biophysical research communications.

Regulation of signal transduction by calcitonin gene-related peptide receptors.

D. Hay, D. Poyner, A. Conner, 2010, Trends in pharmacological sciences.

CGRP receptor heterogeneity: a role for receptor component protein?

D. Hay, D. Poyner, I. Dickerson, 2003, Trends in Endocrinology & Metabolism.

Reply to comment on: A second trigeminal CGRP receptor: function and expression of the AMY1 receptor

D. Hay, C. Walker, 2016, Annals of clinical and translational neurology.

Effect of Adrenomedullin on Migraine-Like Attacks in Patients With Migraine

M. Ashina, D. Hay, N. Arngrim, 2021, Neurology.

Calcitonin Family Receptors

D. Hay, Michael L. Garelja, Michael L Garelja, 2020 .

Structure and Dynamics of Adrenomedullin Receptors AM1 and AM2 Reveal Key Mechanisms in the Control of Receptor Phenotype by Receptor Activity-Modifying Proteins.

P. Sexton, A. Christopoulos, C. Reynolds, 2020, ACS pharmacology & translational science.

Characterisation of agonist signalling profiles and agonist‐dependent antagonism at PACAP‐responsive receptors: Implications for drug discovery

M. Brimble, D. Hay, C. Walker, 2021, British journal of pharmacology.

RAMPs as drug targets.

P. Sexton, A. Christopoulos, D. Hay, 2012, Advances in experimental medicine and biology.

Modulating receptor function through RAMPs: can they represent drug targets in themselves?

P. Sexton, A. Christopoulos, D. Hay, 2009, Drug discovery today.

A narrative review of the calcitonin peptide family and associated receptors as migraine targets: Calcitonin gene‐related peptide and beyond

D. Hay, Michael L. Garelja, Michael L Garelja, 2022, Headache.

Novel Peptide Antagonists of Adrenomedullin and Calcitonin Gene-Related Peptide Receptors: Identification, Pharmacological Characterization, and Interactions with Position 74 in Receptor Activity-Modifying Protein 1/3

R. J. Bailey, D. Hay, D. Poyner, 2009, Journal of Pharmacology and Experimental Therapeutics.

Photoaffinity Cross-Linking and Unnatural Amino Acid Mutagenesis Reveal Insights into Calcitonin Gene-Related Peptide Binding to the Calcitonin Receptor-like Receptor/Receptor Activity-Modifying Protein 1 (CLR/RAMP1) Complex.

C. Reynolds, T. Sakmar, M. Brimble, 2018, Biochemistry.

Photoa ffi nity Cross-Linking and Unnatural Amino Acid Mutagenesis Reveal Insights into Calcitonin Gene-Related Peptide Binding to the Calcitonin Receptor-like Receptor / Receptor Activity-Modifying Protein 1 ( CLR / RAMP 1 ) Complex

C. Reynolds, T. Sakmar, M. Brimble, 2018 .

Amylin antibodies frequently display cross-reactivity with CGRP: characterization of eight amylin antibodies.

D. Hay, C. Walker, T. Rees, 2021, American journal of physiology. Regulatory, integrative and comparative physiology.

Is calcitonin gene-related peptide a reliable biochemical marker of migraine?

D. Hay, A. Hougaard, W. Karlsson, 2022, Current opinion in neurology.

CGRP receptor antagonists for migraine. Are they also AMY1 receptor antagonists?

D. Hay, Michael L. Garelja, C. Walker, 2021, British journal of pharmacology.

CGRP receptor antagonist activity of olcegepant depends on the signalling pathway measured

D. Hay, A. Russo, C. Walker, 2018, Cephalalgia : an international journal of headache.

Complexing Receptor Pharmacology

P. Sexton, A. Christopoulos, D. Hay, 2006 .

Calcitonin Gene-Related Peptide Receptor*

D. Hay, 2007 .

The third extracellular loop of the human calcitonin receptor‐like receptor is crucial for the activation of adrenomedullin signalling

D. Hay, J. Kato, K. Kitamura, 2012, British journal of pharmacology.

PAC1, VPAC1, and VPAC2 Receptor Expression in Rat and Human Trigeminal Ganglia: Characterization of PACAP-Responsive Receptor Antibodies

M. Brimble, D. Hay, S. O'Carroll, 2022, International journal of molecular sciences.

Mapping the calcitonin receptor in human brain stem.

R. Faull, J. Tajti, L. Edvinsson, 2016, American journal of physiology. Regulatory, integrative and comparative physiology.

Characterization of Antibodies against Receptor Activity-Modifying Protein 1 (RAMP1): A Cautionary Tale

D. Hay, K. Caron, T. Lutz, 2022, International journal of molecular sciences.

Distinct Patterns of Internalization of Different Calcitonin Gene-Related Peptide Receptors.

M. Brimble, D. Hay, P. Harris, 2020, ACS pharmacology & translational science.

THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein‐coupled receptors

Stephen P. H. Alexander, Leigh A. Stoddart, Kalyan C. Tirupula, 2021, British journal of pharmacology.

Complexing receptor pharmacology: modulation of family B G protein-coupled receptor function by RAMPs.

P. Sexton, A. Christopoulos, D. Hay, 2006, Annals of the New York Academy of Sciences.

Vasopressin-oxytocin–type signaling is ancient and has a conserved water homeostasis role in euryhaline marine planarians

Masa-aki Yoshida, D. Hay, M. Hamada, 2022, Science advances.

CGRP in the trigeminovascular system: a role for CGRP, adrenomedullin and amylin receptors?

D. Hay, C. Walker, 2013, British journal of pharmacology.

Amylin: Pharmacology, Physiology, and Clinical Potential

D. Hay, D. Parkes, T. Lutz, 2015, Pharmacological Reviews.

Synthesis and amylin receptor activity of glycomimetics of pramlintide using click chemistry.

M. Brimble, Rebekah L. Bower, D. Hay, 2016, Organic & biomolecular chemistry.

Structural insights into RAMP modification of secretin family G protein-coupled receptors: implications for drug development.

J. Archbold, D. Hay, J. Flanagan, 2011, Trends in pharmacological sciences.

Anxiogenic and Stressor Effects of the Hypothalamic Neuropeptide RFRP-3 Are Overcome by the NPFFR Antagonist GJ14.

D. Hay, G. Anderson, G. Painter, 2015, Endocrinology.

Hypervigilance, Allostatic Load, and Migraine Prevention: Antibodies to CGRP or Receptor

D. Hay, P. Durham, A. Blumenfeld, 2021, Neurology and Therapy.

Probing the Mechanism of Receptor Activity-Modifying Protein Modulation of GPCR Ligand Selectivity through Rational Design of Potent Adrenomedullin and Calcitonin Gene-Related Peptide Antagonists.

A. Pioszak, D. Hay, A. Roehrkasse, 2018 .

Probing the Mechanism of Receptor Activity–Modifying Protein Modulation of GPCR Ligand Selectivity through Rational Design of Potent Adrenomedullin and Calcitonin Gene-Related Peptide Antagonists

A. Pioszak, D. Hay, A. Roehrkasse, 2018, Molecular Pharmacology.

Convergent chemoenzymatic synthesis of a library of glycosylated analogues of pramlintide: structure-activity relationships for amylin receptor agonism.

M. Brimble, D. Hay, Yusuke Tomabechi, 2014, Organic & biomolecular chemistry.

Migraine: disease characterisation, biomarkers, and precision medicine

N. Hadjikhani, L. Schulte, P. Goadsby, 2021, The Lancet.

Conclusions and Future Perspectives

D. Hay, 2010 .

Calcitonin gene-related peptide, adrenomedullin and flushing.

D. Hay, D. Poyner, 2009, Maturitas.

CGRP receptor antagonists: design and screening

D. Hay, D. Poyner, A. Conner, 2009, Expert opinion on drug discovery.

A key role for transmembrane prolines in calcitonin receptor-like receptor agonist binding and signalling: implications for family B G-protein-coupled receptors.

D. Hay, J. Simms, M. Wheatley, 2005, Molecular pharmacology.

Characterization of CGRP Receptor Binding

D. Hay, D. Poyner, A. Conner, 2004, Current protocols in pharmacology.

The calcitonin gene-related peptide family

D. Hay, I. Dickerson, 2010 .

Beyond CGRP: The calcitonin peptide family as targets for migraine and pain

D. Hay, C. Walker, T. Rees, 2021, British journal of pharmacology.

Molecular Signature for Receptor Engagement in the Metabolic Peptide Hormone Amylin.

D. Raleigh, C. Reynolds, A. Pioszak, 2018, ACS pharmacology & translational science.

Elucidating the Interactome of G Protein-Coupled Receptors and Receptor Activity-Modifying Proteins

T. Sakmar, D. Hay, Emily Lorenzen, 2022, Pharmacological Reviews.

The receptor activity modifying protein family of G protein coupled receptor accessory proteins.

Patrick M Sexton, Debbie L Hay, P. Sexton, 2004, Seminars in cell & developmental biology.

Amylin Analog Pramlintide Induces Migraine‐like Attacks in Patients

L. Skovgaard, N. Jørgensen, M. Brimble, 2021, Annals of neurology.

Molecular studies of CGRP and the CGRP family of peptides in the central nervous system

Rebekah L. Bower, D. Hay, C. Walker, 2019, Cephalalgia : an international journal of headache.

A second trigeminal CGRP receptor: function and expression of the AMY1 receptor

P. Insel, L. Edvinsson, Rebekah L. Bower, 2015, Annals of clinical and translational neurology.

New Insights into the Regulation of CGRP-Family Receptors.

D. Hay, J. Gingell, E. Hendrikse, 2019, Trends in pharmacological sciences.

Functional characterization of two human receptor activity-modifying protein 3 variants

R. J. Bailey, D. Hay, D. Poyner, 2010, Peptides.

The Molecular Control of Calcitonin Receptor Signaling.

Arthur Christopoulos, Ming-Wei Wang, Erney Ramírez-Aportela, 2019, ACS pharmacology & translational science.

The pharmacology of CGRP-responsive receptors in cultured and transfected cells

D. Hay, J. Simms, D. Poyner, 2004, Peptides.

RAMPs as allosteric modulators of the calcitonin and calcitonin-like class B G protein-coupled receptors.

A. Pioszak, D. Hay, 2020, Advances in pharmacology.

An allosteric role for receptor activity-modifying proteins in defining GPCR pharmacology

P. Sexton, A. Pioszak, D. Hay, 2016, Cell Discovery.

Receptor activity-modifying proteins; multifunctional G protein-coupled receptor accessory proteins.

G. Ladds, C. Reynolds, D. Hay, 2016, Biochemical Society transactions.

Structural Basis for Receptor Activity-Modifying Protein-Dependent Selective Peptide Recognition by a G Protein-Coupled Receptor

A. Pioszak, M. Brimble, R. Bill, 2015, Molecular cell.

Receptor activity-modifying protein-dependent effects of mutations in the calcitonin receptor-like receptor: implications for adrenomedullin and calcitonin gene-related peptide pharmacology

R. J. Bailey, D. Hay, D. Poyner, 2014, British journal of pharmacology.

Pharmacological characterisation of mouse calcitonin and calcitonin receptor‐like receptors reveals differences compared with human receptors

M. Brimble, Rebekah L. Bower, D. Hay, 2021, British journal of pharmacology.

Pharmacological Discrimination of Calcitonin Receptor: Receptor Activity-Modifying Protein Complexes

P. Sexton, A. Christopoulos, D. Hay, 2005, Molecular Pharmacology.

Obesity pharmacotherapy: incretin action in the central nervous system.

D. Hay, A. Tups, G. Boer, 2022, Trends in pharmacological sciences.

Identification of key residues involved in adrenomedullin binding to the AM1 receptor

J. Archbold, M. Brimble, J. Moore, 2013, British journal of pharmacology.

Receptor Activity Modifying Proteins Have Limited Effects on the Class B G Protein-Coupled Receptor Calcitonin Receptor-Like Receptor Stalk.

Sung‐Hyun Yang, M. Brimble, D. Hay, 2018, Biochemistry.

A structural basis for amylin receptor phenotype

P. Sexton, A. Christopoulos, R. Danev, 2022, Science.

Identification of Small-Molecule Positive Modulators of Calcitonin-like Receptor-Based Receptors.

G. Pairaudeau, C. Reynolds, A. Pioszak, 2020, ACS pharmacology & translational science.

Novel Fluorescently Labeled PACAP and VIP Highlight Differences between Peptide Internalization and Receptor Pharmacology.

M. Brimble, D. Hay, C. Walker, 2022, ACS pharmacology & translational science.

Receptor Activity-modifying Proteins 2 and 3 Generate Adrenomedullin Receptor Subtypes with Distinct Molecular Properties

Christopher A. Reynolds, Margaret A. Brimble, Alex C. Conner, 2016, The Journal of Biological Chemistry.

Bruck Taddese, Graham J. G. Upton, Christopher A. Reynolds, 2013, Journal of The Royal Society Interface.

Editorial: Calcitonin Gene-Related Peptide: Novel Biology and Treatments

D. Hay, S. Brain, Andrew F. Russo, 2022, Frontiers in physiology.

Heterodimers and family-B GPCRs: RAMPs, CGRP and adrenomedullin.

D. Hay, J. Simms, M. Wheatley, 2004, Biochemical Society transactions.

Deconvoluting the Molecular Control of Binding and Signaling at the Amylin 3 Receptor: RAMP3 Alters Signal Propagation through Extracellular Loops of the Calcitonin Receptor.

P. Sexton, A. Christopoulos, C. Reynolds, 2019, ACS pharmacology & translational science.

Extracellular loops 2 and 3 of the calcitonin receptor selectively modify agonist binding and efficacy

P. Sexton, A. Christopoulos, C. Reynolds, 2018, Biochemical pharmacology.

The role of ECL2 in CGRP receptor activation: a combined modelling and experimental approach

C. Reynolds, D. Hay, D. Poyner, 2013, Journal of The Royal Society Interface.

The role of ECL 2 in CGRP receptor activation : a combined modelling and experimental approach

C. Reynolds, D. Hay, D. Poyner, 2013 .

The structure of secretin family GPCR peptide ligands: implications for receptor pharmacology and drug development.

D. Hay, Harriet A. Watkins, M. Au, 2012, Drug discovery today.

Class B GPCR: Receptors and RAMPs

D. Hay, J. Gingell, C. Walker, 2017 .

Structure-function analysis of RAMP1 by alanine mutagenesis.

R. J. Bailey, D. Hay, J. Simms, 2009, Biochemistry.

Calcitonin receptors in GtoPdb v.2021.2

D. Hay, D. Poyner, C. Walker, 2021, IUPHAR/BPS Guide to Pharmacology CITE.

Calcitonin receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database

D. Hay, D. Poyner, Debbie L. Hay, 2019, IUPHAR/BPS Guide to Pharmacology CITE.

Stimulation of Posterior Thalamic Nuclei Induces Photophobic Behavior in Mice

J. Wemmie, D. Hay, A. Russo, 2020, Headache.

Interaction of calcitonin-gene-related peptide with its receptors.

Ű. Langel, Ü. Langel, D. Hay, 2001, Biochemical Society transactions.

Adrenomedullin: receptor and signal transduction.

D. Withers, D. Hay, D. Poyner, 2002, Biochemical Society transactions.

Amylin receptors: molecular composition and pharmacology.

A. Christopoulos, D. Hay, G. Christopoulos, 2004, Biochemical Society transactions.

Analysis of Amylin Consensus Sequences Suggests that Human Amylin is Not Optimized to Minimize Amyloid Formation and Provides Clues to Factors that Modulate Amyloidogenicity.

D. Raleigh, Rebekah L. Bower, D. Hay, 2020, ACS chemical biology.

Structure and dynamics of the CGRP receptor in apo and peptide-bound forms

K. Gregory, P. Sexton, A. Christopoulos, 2021, Science.

Calcitonin and calcitonin receptor‐like receptors: common themes with family B GPCRs?

J. Archbold, D. Hay, D. Poyner, 2012, British journal of pharmacology.

Molecular Mechanisms of Class B GPCR Activation: Insights from Adrenomedullin Receptors.

P. Sexton, Sung‐Hyun Yang, M. Brimble, 2020, ACS pharmacology & translational science.

Receptor activity-modifying protein dependent and independent activation mechanisms in the coupling of calcitonin gene-related peptide and adrenomedullin receptors to Gs

C. Reynolds, D. Hay, J. Simms, 2017, Biochemical pharmacology.

Calcitonin and Amylin Receptor Peptide Interaction Mechanisms

A. Pioszak, D. Hay, Sangmin Lee, 2016, The Journal of Biological Chemistry.

PACAP receptor pharmacology and agonist bias: analysis in primary neurons and glia from the trigeminal ganglia and transfected cells

D. Hay, T. Sundrum, C. Walker, 2014, British journal of pharmacology.

Structure–function relationships of the N‐terminus of receptor activity‐modifying proteins

D. Hay, T. Qi, 2010, British journal of pharmacology.

Activity of pramlintide, rat and human amylin but not Aβ1-42 at human amylin receptors.

D. Hay, J. Gingell, Erica R. Burns, 2014, Endocrinology.

Receptor activity modifying proteins and their potential as drug targets.

P. Sexton, A. Christopoulos, D. Hay, 2010, Progress in molecular biology and translational science.

Determinants of 1-Piperidinecarboxamide, N-[2-[[5-Amino-l-[[4-(4-pyridinyl)-l-piperazinyl]carbonyl]pentyl]amino]-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl) (BIBN4096BS) Affinity for Calcitonin Gene-Related Peptide and Amylin Receptors—The Role of Rec

P. Sexton, A. Christopoulos, D. Hay, 2006, Molecular Pharmacology.

Novel Genetic Variant of a Class B G Protein-Coupled Receptor Reveals a Role for Adrenomedullin in Human Fertility.

D. Hay, 2018, ACS pharmacology & translational science.

Knockouts and transgenics confirm the importance of adrenomedullin in the vasculature.

D. Hay, D. Smith, 2001, Trends in pharmacological sciences.

Atogepant (Qulipta) for migraine prevention.

D. Hay, C. Walker, Paul W R Harris, 2021, The Medical letter on drugs and therapeutics.

CGRP physiology, pharmacology, and therapeutic targets: Migraine and beyond.

D. Hay, A. Russo, 2022, Physiological reviews.

Agonist‐dependent consequences of proline to alanine substitution in the transmembrane helices of the calcitonin receptor

R. J. Bailey, D. Hay, 2007, British journal of pharmacology.

Measurement of Phosphorylated Extracellular Signal–Regulated Kinase 1 and 2 in an Undergraduate Teaching Laboratory with ALPHAscreen Technology

Debbie L Hay, D. Hay, 2009, Science Signaling.

Calcitonin receptor antibody validation and expression in the rodent brain

D. Hay, P. Wookey, T. Lutz, 2022, Cephalalgia : an international journal of headache.

Solid-Phase Thiol-Ene Lipidation of Peptides for the Synthesis of a Potent CGRP Receptor Antagonist.

M. Brimble, D. Hay, Elyse T. Williams, 2018, Angewandte Chemie.

Solid-Phase Thiol-Ene Lipidation of Peptides for the Synthesis of a Potent CGRP Receptor Antagonist